Effect of Statin Use on Outcome of Symptomatic Cholelithiasis: a Case-control Study

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2014 Jul 5

PMID 24993977

Citations 1

Authors

Jukka Pulkkinen

Matti Eskelinen

Vesa Kiviniemi

Tuukka Kotilainen

Markus Poyhonen

Lasse Kilpelainen

Pirjo Kakela

Helena Kastarinen

Hannu Paajanen

Affiliations

Soon will be listed here.

Abstract

Background: Statins can modify bile cholesterol and, thus, the formation of gallstones. We examined whether statin use also modifies the severity of symptomatic gallstone disease and its treatment.

Methods: A total of 1,140 consecutive patients with symptomatic gallstone disease were recruited during 2008-2010 at Kuopio university hospital, Finland. Case-control analysis matched the patients using (n = 272) or not using (n = 272) statins by age and sex. The baseline characteristics of the patients, need and type of surgical treatment, duration of operation, perioperative bleeding, postoperative complications and overall mortality rate were compared statistically between the study groups.

Results: Morbidity and subsequent polypharmacy occurred more frequently among the patients with statins compared to the patients without statins. There were no significant differences between the statin users and non-users regarding surgical treatment (open vs. laparoscopic cholecystectomy). The mean operation time for laparoscopic cholecystectomy was 10% shorter for the patients with statin use than for the patients without. In addition, there was a non-significant tendency for statin users to bleed less during laparoscopic operations than the non-users. There were no differences in other procedure-related parameters (e.g., operation urgency, conversions, choledochotomies, complications and mortality) in patients with or without statins.

Conclusions: Compared to no treatment, statin treatment was associated with a shorter operation time for laparoscopy cholecystectomy. Other surgical outcome parameters were similar in patients with or without statins, although statin users had more polypharmacy and circulatory illnesses than non-users.

Citing Articles

Association between Gallstone Disease and Statin Use: A Nested Case-Control Study in Korea.

Kwon M, Lee J, Kang H, Lim H, Kim E, Kim N Pharmaceuticals (Basel). 2023; 16(4).

PMID: 37111293 PMC: 10143191. DOI: 10.3390/ph16040536.

References

Bodmer M, Brauchli Y, Krahenbuhl S, Jick S, Meier C . Statin use and risk of gallstone disease followed by cholecystectomy. JAMA. 2009; 302(18):2001-7. DOI: 10.1001/jama.2009.1601. View

Banim P, Luben R, Bulluck H, Sharp S, Wareham N, Khaw K . The aetiology of symptomatic gallstones quantification of the effects of obesity, alcohol and serum lipids on risk. Epidemiological and biomarker data from a UK prospective cohort study (EPIC-Norfolk). Eur J Gastroenterol Hepatol. 2011; 23(8):733-40. DOI: 10.1097/MEG.0b013e3283477cc9. View

Chuang S, Hsi E, Lee K . Genetics of gallstone disease. Adv Clin Chem. 2013; 60:143-85. DOI: 10.1016/b978-0-12-407681-5.00005-2. View

Festi D, Bacchi Reggiani M, Attili A, Loria P, Pazzi P, Scaioli E . Natural history of gallstone disease: Expectant management or active treatment? Results from a population-based cohort study. J Gastroenterol Hepatol. 2010; 25(4):719-24. DOI: 10.1111/j.1440-1746.2009.06146.x. View

Suuronen S, Niskanen L, Paajanen P, Paajanen H . Declining cholecystectomy rate during the era of statin use in Finland: a population-based cohort study between 1995 and 2009. Scand J Surg. 2013; 102(3):158-63. DOI: 10.1177/1457496913492463. View

Jain M, Ridker P . Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov. 2005; 4(12):977-87. DOI: 10.1038/nrd1901. View

Stinton L, Myers R, Shaffer E . Epidemiology of gallstones. Gastroenterol Clin North Am. 2010; 39(2):157-69, vii. DOI: 10.1016/j.gtc.2010.02.003. View

Shaffer E . Gallstone disease: Epidemiology of gallbladder stone disease. Best Pract Res Clin Gastroenterol. 2006; 20(6):981-96. DOI: 10.1016/j.bpg.2006.05.004. View

Wang H, Portincasa P, de Bari O, Liu K, Garruti G, Neuschwander-Tetri B . Prevention of cholesterol gallstones by inhibiting hepatic biosynthesis and intestinal absorption of cholesterol. Eur J Clin Invest. 2013; 43(4):413-26. PMC: 3996849. DOI: 10.1111/eci.12058. View

10.

Fujita T . Use of statins and gallstone risk. JAMA. 2010; 303(12):1146-7. DOI: 10.1001/jama.2010.321. View

11.

Chiu H, Chen C, Kuo H, Lee I, Wu T, Yang C . Statin use and the risk of gallstone disease: a population-based case-control study. Expert Opin Drug Saf. 2012; 11(3):369-74. DOI: 10.1517/14740338.2012.653560. View

12.

Russo M, Wei J, Thiny M, Gangarosa L, Brown A, Ringel Y . Digestive and liver diseases statistics, 2004. Gastroenterology. 2004; 126(5):1448-53. DOI: 10.1053/j.gastro.2004.01.025. View

13.

Ong K, Wu B, Cheung B, Barter P, Rye K . Association of lower total bilirubin level with statin usage: the United States National Health and Nutrition Examination Survey 1999-2008. Atherosclerosis. 2011; 219(2):728-33. DOI: 10.1016/j.atherosclerosis.2011.07.094. View

14.

Tsai C, Leitzmann M, Willett W, Giovannucci E . Statin use and the risk of cholecystectomy in women. Gastroenterology. 2009; 136(5):1593-600. PMC: 3668330. DOI: 10.1053/j.gastro.2009.01.042. View

15.

Tsai C, Leitzmann M, Willett W, Giovannucci E . Prospective study of abdominal adiposity and gallstone disease in US men. Am J Clin Nutr. 2004; 80(1):38-44. DOI: 10.1093/ajcn/80.1.38. View

16.

Ruokoniemi P, Helin-Salmivaara A, Klaukka T, Neuvonen P, Huupponen R . Shift of statin use towards the elderly in 1995-2005: a nation-wide register study in Finland. Br J Clin Pharmacol. 2008; 66(3):405-10. PMC: 2526244. DOI: 10.1111/j.1365-2125.2008.03258.x. View

17.

Smith J, Roach P, Wittenberg L, Riottot M, Pillay S, Nestel P . Effects of simvastatin on hepatic cholesterol metabolism, bile lithogenicity and bile acid hydrophobicity in patients with gallstones. J Gastroenterol Hepatol. 2000; 15(8):871-9. DOI: 10.1046/j.1440-1746.2000.02231.x. View

18.

Portincasa P, Moschetta A, Palasciano G . Cholesterol gallstone disease. Lancet. 2006; 368(9531):230-9. DOI: 10.1016/S0140-6736(06)69044-2. View

19.

Patel J, Abd T, Blumenthal R, Nasir K, Superko H . Genetics and personalized medicine--a role in statin therapy?. Curr Atheroscler Rep. 2013; 16(1):384. DOI: 10.1007/s11883-013-0384-y. View

20.

Marschall H, Einarsson C . Gallstone disease. J Intern Med. 2007; 261(6):529-42. DOI: 10.1111/j.1365-2796.2007.01783.x. View